Slovak News Back to the news
Government: Purchase of A/H1N1 Vaccines Advantageous
Wednesday 27 January 2010 Zoom in | Print page
Bratislava, January 27 (TASR) - The contract on the purchase of novel-flu (A/H1N1) vaccines, which was signed between Slovakia and French company Sanofi Pasteur at the end of 2009 is economically profitable for Slovakia, reads Health Ministry's report submitted to Slovak Government on Wednesday.
The Ministry draws this conclusion based on the fact that the final price per one vaccine of €7.60 includes its distribution costs as well as a syringe and a needle. The Slovak Government has now okayed the report, which is to be presented in Slovak Parliament by Health Minister Richard Rasi (who is currently in Vietnam).
"For example, in the Czech Republic all the additional costs for the distribution and application of the vaccine were covered by the state," reads the material.
According to the report, four companies were addressed after the Slovak Government okayed the purchase of 1 million doses of vaccine in September, while negotiations were held with three of the companies. Two companies applied for the tender - GlaxoSmithKline and Sanofi Pasteur. Third company Novartis did not enter the tender. Within the given period of the tender, only one proposal was submitted - from Sanofi Pasteur. The French company signed the contract on November 30, 2009.
All rights reserved. Any publishing or further dissemination of press releases and photographs from TASR's resources without TASR's prior written approval constitutes a violation of the Copyrights Act.
